CNTG CENTOGENE: Price-to-Projected Revenue Ratio

Centogene NV (CNTG) - corporate logo

The forward P/S trend on GURU.Markets illustrates the valuation of Centogene N.V. (CNTG) relative to expected sales, with the metric currently standing at 0.20. The company faces threats from liquidity shortages and the risk of sequencing method obsolescence. Biobank expenses and declining insurance reimbursements are weighing on profits. Meanwhile, a unique dataset allows the company to maintain pricing power with pharma behemoths despite pressure within the clinical segment.

CNTG (CENTOGENE N.V.) Price to Expected Revenue Ratio history from 07/04/2022 to 08/10/2024

Analytical breakdowns and data insights for company Centogene (CNTG)

- current price and projected stock value:
Stock Price Centogene NV|CNTG - Average Forecast Price
- company stock capitalization data:
Market Value Centogene|CNTG - Business Value
- book value of equity indicators:
Accounting Value per Share CENTOGENE|CNTG - Total Net Assets|Market Value to Book Value Ratio centogene.com|CNTG - Company Assets
- company total debt and liquidity indicators:
Total Debt to Capital Centogene N.V.|CNTG - Long-Term Indebtedness to Equity|Short-Term Debt to Capital Centogene N.V.|CNTG - Company Cumulative Debt|Debt to Book Capitalization Ratio Centogene|CNTG - Company Long-Term Indebtedness|Company Short-Term Debts CENTOGENE|Quick Liquidity Indicator centogene.com
- net income and valuation multiples indicators:
CNTG - Final Profit|Expected Profit Centogene N.V.|CNTG - Price to Earnings Multiple|Projected Price to Earnings CENTOGENE N.V.|CNTG - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Centogene|CNTG - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months CENTOGENE|CNTG - Net earnings per share for the last four quarters|Quarterly EPS earnings growth centogene.com|CNTG - Net earnings per share growth this year|Net earnings per share growth forecast for next year Centogene N.V.
- issuer revenue and sales details:
CNTG - Company Sales Volume|Company Future Sales Volume Centogene|CNTG - Market Cap to Sales Volume|Forward P/S Multiple Centogene
Initial company analysis:CNTG (CENTOGENE)
Product sample of Centogene

Forward P/S measures a company's market value relative to expected future sales, allowing for an assessment of whether the business is undervalued or faces the risk of revenue stagnation. By analyzing the current forward P/S level, an investor can align market expectations with the value of Centogene N.V. (CNTG) and its massive genetic mutation database, which provides the company with a strategic advantage in developing targeted therapies.

Competitor analysis for Centogene N.V.

Forward P/S Multiple A (Agilent)|Quest Diagnostics Inc. (DGX) - Market Cap to Future Revenue Ratio|ILMN - Price-to-Projected Revenue Ratio|EXAS (Exact Sciences Inc.) - Market Cap to Projected Revenue|RVTY (Revvity, Inc.) - Forward Price-to-Revenue Multiple|BIO: Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio Anbio|Market Cap to Future Revenue Ratio Sotera Health Corp SHC|Forward P/S Multiple QDEL|OPKO Health Corp. (OPK) - Projected Price to Revenue|Forward P/S Multiple CDNA (CareDx, Inc)|maravai.com (MRVI) - Market Cap to Future Revenue Ratio|FLGT - Price-to-Projected Revenue Ratio|LAB (Standard BioTools Inc) - Market Cap to Projected Revenue|CTKB: Forward P/S Multiple|Market Cap to Future Revenue Ratio OraSure Corp (OSUR)|Forward Price-to-Revenue Multiple XGN|MDXH: Forward Price to Sales|Price-to-Projected Revenue Ratio Lucid Diagnostics (LUCD)|prenetics.com - Market Cap to Projected Revenue|Insight Molecular Diagnostics Inc - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Trinity Biotech PLC (TRIB)|PRPH: Forward Price-to-Revenue Multiple|AIMD: Price-to-Projected Revenue Ratio|CODX (Co-Diagnostics) - Forward Price-to-Revenue Multiple|HSCS - Market Cap to Expected Sales Ratio|BMRA (Biomerica, Inc) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Cardio Diagnostics Holdings, Inc. (CDIO)|Price-to-Projected Revenue Ratio Onconetix, Inc. (ONCO)|viraxbiolabs.com - Market Cap to Projected Revenue|Bluejay Diagnostics, Inc. - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio AWH (Aspira Women's Health, Inc.)|Accelerate Diagnostics, Inc - Forward P/S Multiple|Projected Price to Revenue Enzo Biochem, Inc. (ENZ)|fresh2.co (FRES) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Genetic Technologies Limited|ME (23andMe) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Psychemedics Corp. PMD